| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
FTO-IN-16 (0-8 μM; 48 hours) downregulated the expression of c-Myc and CEBPA (protein and mRNA) in various AML cells (NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1) and upregulated the expression of ASB2 and RARA [1]. FTO-IN-16 (0-20 μM; 48 hours) induced dose-dependent apoptosis in NB4 cells [1]. FTO-IN-16 (0-8 μM; 48 hours) downregulated the expression of c-Myc and CEBPA (protein and mRNA) in various AML cells (NB4, MOLM13, MV4-11, HEL, OCI-AML3, NOMO-1, KG-1) and upregulated the expression of ASB2 and RARA [1]. FTO-IN-16 (72 hours) showed strong anti-leukemic activity against a series of AML cell lines, with IC50 values of 5.5 (NB4), 2.3 (MOLM13), 4.4 (KG-1), 3.6 (MV4-11), 4.6 (HEL), 5.2 (OCI-AML3) and 4.7 μM (NOMO-1)[1].
|
|---|---|
| ln Vivo |
FTO-IN-16 (30 and 60 mg/kg; intraperitoneal injection; once daily for 9 days) inhibits the progression of AML through m6A-mediated transcriptional regulation in a mouse xenograft model [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: MOLM13 Tested Concentrations: 0, 2, 4, 8 μM Incubation Duration: 24, 48, 72 hours Experimental Results: Time-dependent growth inhibition was induced. Compared with the control group, cell growth was significantly inhibited after 72 hours of treatment with 8 μM. |
| Animal Protocol |
Animal/Disease Models:Subcutaneous injection of NB4 AML cells [1] into female BALB/c nude mice. Dose: 30 and 60 mg/kg.
Route of Administration: Intraperitoneal injection; once daily for 9 consecutive days. Experimental Results: Significantly inhibited tumor growth in a dose-dependent manner. No significant weight loss or organ toxicity was observed. It led to upregulation of tumor suppressor genes (RARA, ASB2) and downregulation of oncoproteins (CEBPA, c-Myc). Significantly increased RNA m6A modification levels were observed. |
| References |
| Molecular Formula |
C23H23CL2N3O6
|
|---|---|
| Molecular Weight |
508.35
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C(C1=CC=CC=C1NC2=C(C=C(C=C2Cl)C(NCCNC(/C=C/C(OCC)=O)=O)=O)Cl)OC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9671 mL | 9.8357 mL | 19.6715 mL | |
| 5 mM | 0.3934 mL | 1.9671 mL | 3.9343 mL | |
| 10 mM | 0.1967 mL | 0.9836 mL | 1.9671 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
